ArticleBMC endocrine disorders2016
Elevated circulating irisin is associated with lower risk of insulin resistance: association and path analyses of obese Chinese adults.
Article in BMC endocrine disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Exercise-induced irisin release as a determinant of the metabolic response to exercise training in obese youth: the EXIT trial.Physiological reports · 2017Trial
- Irisin, Brain-Derived Neurotrophic Factor (BDNF), and Redox Balance in Geriatric Dynapenia.Antioxidants (Basel, Switzerland) · 2025Article
- Irisin: Emerging Therapeutic Targets for Cognitive Impairment-Related Diseases.Expert reviews in molecular medicine · 2025Review
- Low irisin levels are associated with increased body weight and an adverse metabolic profile.Archives of endocrinology and metabolism · 2025Article
- Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions.ImmunoTargets and therapy · 2025Review
- Bone Health and Physical Activity - The Complex Mechanism.Aging and disease · 2024Review
- Article
- Increased Circulating Irisin Levels in Kidney Transplant Patients: Is There a Connection with Glycaemic Control?International journal of molecular sciences · 2024Article
- Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity.Metabolites · 2023Review
- Irisin and Cardiometabolic Disorders in Obesity: A Systematic Review.International journal of inflammation · 2023Review
- A Bibliometric Analysis of the Literature on Irisin from 2012-2021.International journal of environmental research and public health · 2022Review
- Irisin participates in the beneficial effects of exercise in preventing gestational diabetes mellitus in overweight and obese pregnant women and a mouse model.Frontiers in nutrition · 2022Article
- Effect of Irisin on LIF and integrin αvβ3 in rats of implantation failure.Reproductive biology and endocrinology : RB&E · 2021Article
- Article
- Serum irisin levels in metabolically healthy versus metabolically unhealthy obesity: A case-control study.Medical journal of the Islamic Republic of Iran · 2020Article
- The association of circulating irisin with metabolic risk factors in Chinese adults: a cross-sectional community-based study.BMC endocrine disorders · 2019Article
- Circulating Irisin and Myostatin as Markers of Muscle Strength and Physical Condition in Elderly Subjects.Frontiers in physiology · 2019Article
- Irisin: A Hope in Understanding and Managing Obesity and Metabolic Syndrome.Frontiers in endocrinology · 2019Review
- Increased FNDC5 is associated with insulin resistance in high fat-fed mice.Physiological reports · 2017Article
- Anti-Inflammatory Properties of Irisin, Mediator of Physical Activity, Are Connected with TLR4/MyD88 Signaling Pathway Activation.International journal of molecular sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence on the role of irisin in insulin resistance is limited and controversial, and pathways between them remain unknown. We aimed to examine the independent effects of circulating irisin and different adiposity measurements, as well as their potential interactions, on insulin resistance. We also aimed to explore possible pathways among circulating irisin, adiposity, glucose and insulin levels and insulin resistance.
methodsA cross-sectional study of 1,115 community- living obese Chinese adults, with data collection on clinical characteristics, glucose and lipid metabolic parameters and circulating irisin levels.
resultsAmong the 1,115 subjects, 667 (59.8 %) were identified as insulin-resistance, and showed significantly decreased serum irisin than their controls (log-transformed irisin: 1.19 ± 2.34 v.s. 1.46 ± 2.05 ng/ml, p = 0.042). With adjustment for potential confounders, elevated circulating irisin was significantly associated with reduced risk of insulin resistance, with adjusted odds ratio per standard deviation increase of irisin of 0.871 (0.765-0.991, p = 0.036). As for different adiposity measurements, body fat percentage, but neither BMI nor waist, was significantly associated with increased risk of insulin resistance (OR: 1.152 (1.041-1.275), p = 0.006). No significant interaction effect between serum irisin and adiposity on insulin resistance was found. A one pathway model about the relationship between serum irisin and insulin resistance fits well (χ (2) = 44.09, p < 0.001; CFI-0.994; TLI =0.986; and RMSEA = 0.067), and shows that elevated circulating irisin might improve insulin resistance indirectly through lowering fasting insulin levels (standardized path coefficient = -0.046, p = 0.032).
conclusionsElevated circulating irisin is associated with lower risk of insulin resistance indirectly through lowering fasting insulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.